Jan 8 (Reuters) - Inovio Pharmaceuticals Inc:
* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:
 